ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Studer, S.M.
Right arrow Articles by Orens, J.B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Studer, S.M.
Right arrow Articles by Orens, J.B.
Eur Respir J 2004; 24:674-685
Copyright ©ERS Journals Ltd 2004

Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness

S.M. Studer1, R.D. Levy2, K. McNeil3 and J.B. Orens4

1 The University of Pittsburgh Medical Center, Division of Pulmonary, Allergy and Critical Care Medicine, Pittsburgh, PA, 4 Johns Hopkins Hospital, Baltimore, MD, USA, 2 St. Paul's Hospital and 3 British Colombia Transplant Society, Vancouver, BC, Canada.

CORRESPONDENCE: J.B. Orens, Johns Hopkins Hospital, 1830 E Monument St, 5th floor, Baltimore, MD 21205, USA. Fax: 1 4109550036, E-mail: Jorens@jhmi.edu

Keywords: Cost, function, lung transplantation, outcomes, quality of life, survival

Received: June 3, 2004
Accepted June 6, 2004

Abstract

The success of lung transplantation has improved over time as evidenced by better long-term survival and functional outcomes. Despite the success of this procedure, there are numerous problems and complications that may develop over the life of a lung transplant recipient. With proper monitoring and treatment, the frequency and severity of these problems can be decreased. However, significant improvement for the overall outcomes of lung transplantation will only occur when better methods exist to prevent or effectively treat chronic rejection.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
E. M. Clini and N. Ambrosino
Nonpharmacological treatment and relief of symptoms in COPD
Eur. Respir. J., July 1, 2008; 32(1): 218 - 228.
[Abstract] [Full Text] [PDF]

Home page
 Am J Crit CareHome page
M.-K. Song, A. De Vito Dabbs, S. M. Studer, and S. E. Zangle
Course of Illness after the Onset of Chronic Rejection in Lung Transplant Recipients
Am. J. Crit. Care., May 1, 2008; 17(3): 246 - 253.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
Y. Li, T. Koster, C. Morike, S. v. Horsten, U. Martin, M. Bader, A. Haverich, and A. R. Simon
Pravastatin prolongs graft survival in an allogeneic rat model of orthotopic single lung transplantation.
Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 515 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
A R Glanville
Ethical and equity issues in lung transplantation and lung volume reduction surgery
Chronic Respiratory Disease, January 1, 2006; 3(1): 53 - 58.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the European Respiratory Society.